Synthetic Biologics
Market Cap
US$43.1m
Last Updated
2021/03/04 23:34 UTC
Data Sources
Company Financials +
Executive Summary
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 9.6% per year for the next 3 years
Shareholders have been substantially diluted in the past year
+ 2 more risks
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Synthetic Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 37% a week.
Volatility Over Time: SYN's weekly volatility has increased from 21% to 37% over the past year.
Market Performance
7 Day Return
-15.9%
SYN
-6.0%
US Biotechs
-2.4%
US Market
1 Year Return
32.0%
SYN
20.7%
US Biotechs
31.2%
US Market
Return vs Industry: SYN exceeded the US Biotechs industry which returned 20.7% over the past year.
Return vs Market: SYN matched the US Market which returned 31.2% over the past year.
Shareholder returns
| SYN | Industry | Market | |
|---|---|---|---|
| 7 Day | -15.9% | -6.0% | -2.4% |
| 30 Day | -26.6% | -10.2% | -3.0% |
| 90 Day | 56.8% | -2.6% | 3.2% |
| 1 Year | 32.0%32.0% | 22.6%20.7% | 34.1%31.2% |
| 3 Year | -95.6%-95.6% | 11.7%6.1% | 48.1%38.6% |
| 5 Year | -99.0%-99.0% | 51.1%39.8% | 116.5%92.3% |
Long-Term Price Volatility Vs. Market
How volatile is Synthetic Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?10 months ago | Simply Wall St
Could Synthetic Biologics, Inc.'s (NYSEMKT:SYN) Investor Composition Influence The Stock Price?11 months ago | Simply Wall St
Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market?Valuation
Is Synthetic Biologics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Synthetic Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Examine Synthetic Biologics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Synthetic Biologics regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Synthetic Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-9.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SYN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SYN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Synthetic Biologics performed over the past 5 years?
18.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYN is currently unprofitable.
Growing Profit Margin: SYN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SYN is unprofitable, but has reduced losses over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare SYN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: SYN has a negative Return on Equity (-283.01%), as it is currently unprofitable.
Next Steps
Financial Health
How is Synthetic Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: SYN's short term assets ($6.7M) exceed its short term liabilities ($3.0M).
Long Term Liabilities: SYN's short term assets ($6.7M) exceed its long term liabilities ($261.0K).
Debt to Equity History and Analysis
Debt Level: SYN is debt free.
Reducing Debt: SYN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SYN has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.5% each year.
Next Steps
Dividend
What is Synthetic Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.8yrs
Average board tenure
CEO
Steve Shallcross (59 yo)
3.25yrs
Tenure
US$1,108,609
Compensation
Mr. Steven A. Shallcross, also known as Steve, CPA, has been Independent Director of Elys Game Technology, Corp. (formerly known as Newgioco Group, Inc.). since June 13, 2019. Mr. Shallcross has been the C...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD511.69K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 3.25yrs | US$1.11m | 0.075% $ 32.2k | |
| Director | 0.33yr | no data | no data | |
| Independent Non-Executive Chairman | 8.83yrs | US$242.00k | 0.0098% $ 4.2k | |
| Independent Director | 15.17yrs | US$140.00k | no data | |
| Member of C Difficile Clinical Advisory Board | 6.75yrs | no data | no data | |
| Member of C Difficile Clinical Advisory Board | 6.75yrs | no data | no data | |
| Member of C Difficile Clinical Advisory Board | 6.75yrs | no data | no data | |
| Chairman of C Difficile Clinical Advisory Board | 6.75yrs | no data | no data | |
| Member of Infectious Disease Scientific Advisory Board | 8.42yrs | no data | no data | |
| Member of Intestinal Alkaline Phosphatase Clinical Advisory Board | 0.75yr | no data | no data |
6.8yrs
Average Tenure
58yo
Average Age
Experienced Board: SYN's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SYN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 298.1%.
Top Shareholders
Company Information
Synthetic Biologics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Synthetic Biologics, Inc.
- Ticker: SYN
- Exchange: AMEX
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$43.126m
- Shares outstanding: 66.91m
- Website: https://www.syntheticbiologics.com
Number of Employees
Location
- Synthetic Biologics, Inc.
- 9605 Medical Center Drive
- Suite 270
- Rockville
- Maryland
- 20850
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SFYC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2006 |
| SYN | AMEX (NYSE MKT LLC) | Yes | Common Stock | US | USD | Nov 2006 |
Biography
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II cl...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/04 23:34 |
| End of Day Share Price | 2021/03/04 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.